Isosorbide mononitrate in heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 373, Issue 24, 2015, Pages 2314-2324

  Redfield, Margaret M ^a   Anstrom, Kevin J ^b   Levine, James A ^d   Koepp, Gabe A ^d   Borlaug, Barry A ^a   Chen, Horng H ^a   LeWinter, Martin M ^e   Joseph, Susan M ^f   Shah, Sanjiv J ^g   Semigran, Marc J ^h   Felker, G Michael ^c   Cole, Robert T ^j   Reeves, Gordon R ^k   Tedford, Ryan J ^l   Tang, W H Wilson ⁿ   McNulty, Steven E ^b   Velazquez, Eric J ^b   Shah, Monica R ^m   Braunwald, Eugene ⁱ  

^a MAYO CLINIC   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j EMORY UNIVERSITY   (United States)

^k Thomas Jefferson University   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; ISOSORBIDE MONONITRATE; LOOP DIURETIC AGENT; PLACEBO; BRAIN NATRIURETIC PEPTIDE; ISOSORBIDE DINITRATE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); VASODILATOR AGENT;

ACCELEROMETRY; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; QUALITY OF LIFE; REPRODUCIBILITY; SYSTOLIC BLOOD PRESSURE; WALKING; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; EXERCISE TOLERANCE; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACCELEROMETRY; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; MOTOR ACTIVITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; QUALITY OF LIFE; STROKE VOLUME; VASODILATOR AGENTS; WALKING;

EID: 84949459217     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1510774     Document Type: Article

References (36)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
2. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41: 1510-8.
3. Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol 2015; 12: 294-304.
4. Maurer MS, Schulze PC. Exercise intolerance in heart failure with preserved ejection fraction: shifting focus from the heart to peripheral skeletal muscle. J Am Coll Cardiol 2012; 60: 129-31.
5. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983; 67: 817-22.
6. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-7.
7. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980; 69: 559-66.
8. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 935-44.
9. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARMPreserved Trial. Lancet 2003; 362: 777-81.
10. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-67.
11. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45.
12. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013; 6: 184-92.
13. Zakeri R, Levine JA, Koepp GA, et al. Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. Circ Heart Fail 2015; 8: 221-8.
14. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59: 442-51.
15. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-20.
16. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011; 8: 13-28.
17. von Lueder TG, Atar D. Comorbidities and polypharmacy. Heart Fail Clin 2014; 10: 367-72.
18. Gorman E, Hanson HM, Yang PH, Khan KM, Liu-Ambrose T, Ashe MC. Accelerometry analysis of physical activity and sedentary behavior in older adults: a systematic review and data analysis. Eur Rev Aging Phys Act 2014; 11: 35-49.
19. Cheung VH, Gray L, Karunanithi M. Review of accelerometry for determining daily activity among elderly patients. Arch Phys Med Rehabil 2011; 92: 998-1014.
20. Thompson WG, Kuhle CL, Koepp GA, McCrady-Spitzer SK, Levine JA. "Go4Life" exercise counseling, accelerometer feedback, and activity levels in older people. Arch Gerontol Geriatr 2014; 58: 314-9.
21. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials 2009; 10: 27.
22. Senn S, ed. Cross-over trials in clinical research. 2nd ed. Chichester, United Kingdom: Wiley, 2002.
23. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015; 65: 1668-82.
24. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 doubleblind randomised controlled trial. Lancet 2012; 380: 1387-95.
25. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-77.
26. Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 2015; 162: 123-32.
27. Young DR, Reynolds K, Sidell M, et al. Effects of physical activity and sedentary time on the risk of heart failure. Circ Heart Fail 2014; 7: 21-7.
28. Conraads VM, Spruit MA, Braunschweig F, et al. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail 2014; 7: 279-87.
29. Levine JA, Lanningham-Foster LM, McCrady SK, et al. Interindividual variation in posture allocation: possible role in human obesity. Science 2005; 307: 584-6.
30. Levine JA. Measurement of energy expenditure. Public Health Nutr 2005; 8: 1123-32.
31. Levine J, Melanson EL, Westerterp KR, Hill JO. Tracmor system for measuring walking energy expenditure. Eur J Clin Nutr 2003; 57: 1176-80.
32. Levine J, Melanson EL, Westerterp KR, Hill JO. Measurement of the components of nonexercise activity thermogenesis. Am J Physiol Endocrinol Metab 2001; 281: (4)E670-E675.
33. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006; 114: 2138-47.
34. Zamani P, Rawat D, Shiva-Kumar P, et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 2015; 131: 371-80.
35. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7: 156-67.
36. Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2015; 66: 1672-82.